Evaluating outcomes in cirrhosis related to HIV and simvastatin treatment
Official title: Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10909240 · Data updated 2026-11-12
This study is looking at how simvastatin treatment affects people with cirrhosis who also have HIV, to see how it influences their liver health and related issues like muscle loss and weakness, so we can better understand how to help them feel better and improve their condition.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 23, 2021 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $733,101 |
| NIH project number | 5U01DK130180-04 |
| Project ID | NIH-10909240 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with cirrhosis, especially those who are also HIV positive and may be receiving simvastatin.
✕Less likely to help
Patients without cirrhosis or those not infected with HIV are unlikely to benefit from this research.
What this research studies
This research investigates the outcomes of patients with cirrhosis, particularly focusing on those who are also infected with HIV and are receiving simvastatin therapy. The study aims to understand how these factors influence the progression of liver disease, including complications like sarcopenia and frailty. By analyzing patient data and outcomes over time, the research seeks to identify predictors of disease progression and the potential for reversing liver damage. Patients will be monitored for changes in their health status and the impact of treatment on their liver condition.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with cirrhosis, particularly those co-infected with HIV.
How similar studies have gone: While there has been research on cirrhosis and HIV, this specific approach focusing on simvastatin therapy and its effects on sarcopenia in cirrhosis is relatively novel.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Dasarathy, Srinivasan — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Dasarathy, Srinivasan
Related research
Other NIH-funded projects on the same topics.
-
Outcomes in cirrhosis from different causes and the role of HIV and simvastatin
This study looks at how cirrhosis from alcohol, HIV, and other causes affects patients and whether simvastatin can influence outcomes.
-
How HIV and simvastatin affect outcomes in people with cirrhosis
This project looks at whether having HIV and taking simvastatin change health outcomes for adults with cirrhosis from different causes.
-
Evaluating outcomes in cirrhosis and the effects of HIV and simvastatin
This study is looking at how simvastatin might help people with liver disease from cirrhosis, especially those who also have HIV, by tracking their health and any changes in their strength and overall well-being over time.
-
Understanding how genetic changes in blood cells relate to heart disease in people with HIV
A study will look at how age-related blood cell mutations and large chromosomal changes might contribute to heart disease risk in people living with HIV.
-
Cardiac health and protein markers in kids with perinatal HIV exposure or infection
A study from Duke aims to understand heart health and protein biomarkers in children who were exposed to or infected with HIV at birth, especially in sub-Saharan Africa.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.